Pharmacology Quiz: Ezetimibe And Pcsk9 Inhibitors
20 questions · exam conditions
0:00
Ezetimibe And Pcsk9 InhibitorsQuestion 1 of 20

A patient is stabilized on ezetimibe therapy, which relies on enterohepatic circulation of its active glucuronide metabolite for its duration of action. The patient is subsequently prescribed cholestyramine. Co-administration of these two drugs without appropriate time spacing is expected to cause which pharmacokinetic alteration?

An increase in the half-life of ezetimibe's active metabolite.
A significant decrease in the bioavailability of ezetimibe.
Inhibition of the glucuronidation of ezetimibe in the intestinal wall.
Displacement of ezetimibe from plasma protein binding sites.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Ezetimibe And Pcsk9 Inhibitors

Practice Ezetimibe And Pcsk9 Inhibitors in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Ezetimibe And Pcsk9 Inhibitors, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient is stabilized on ezetimibe therapy, which relies on enterohepatic circulation of its active glucuronide metabolite for its duration of action. The patient is subsequently prescribed cholestyramine. Co-administration of these two drugs without appropriate time spacing is expected to cause which pharmacokinetic alteration?

  1. An increase in the half-life of ezetimibe's active metabolite.
  2. A significant decrease in the bioavailability of ezetimibe. (correct answer)
  3. Inhibition of the glucuronidation of ezetimibe in the intestinal wall.
  4. Displacement of ezetimibe from plasma protein binding sites.
Explanation: Cholestyramine is a bile acid sequestrant that binds non-specifically to anionic compounds in the gut. It will bind to ezetimibe and its active metabolite, preventing their absorption and reabsorption (enterohepatic circulation). This significantly reduces the oral bioavailability and overall drug exposure, leading to reduced efficacy.

Question 2

A patient with established ASCVD and a very high baseline Lipoprotein(a) [Lp(a)] level is on high-intensity statin therapy. Despite achieving their LDL-C goal, their physician is concerned about the residual risk from the elevated Lp(a). The addition of which agent would be expected to produce the most clinically meaningful reduction in Lp(a) levels?

  1. Ezetimibe
  2. Evolocumab (correct answer)
  3. Colesevelam
  4. Fenofibrate
Explanation: PCSK9 inhibitors, such as evolocumab and alirocumab, have been shown to significantly reduce Lp(a) levels, typically by 20-30%. While the exact mechanism is still being elucidated, it is thought to be related to increased clearance via the LDL receptor. Other agents like ezetimibe, statins, and fibrates have minimal or negligible effects on Lp(a) concentrations.

Question 3

A heart transplant recipient stabilized on a cyclosporine-based immunosuppressive regimen requires lipid-lowering therapy with ezetimibe. What is the most significant pharmacokinetic interaction of concern when these two drugs are co-administered?

  1. A significant decrease in cyclosporine levels, risking transplant rejection.
  2. A significant decrease in ezetimibe efficacy due to induced metabolism.
  3. Increased risk of myopathy independent of any change in drug concentrations.
  4. Bidirectional increase in plasma concentrations of both cyclosporine and ezetimibe. (correct answer)
Explanation: Co-administration of cyclosporine and ezetimibe results in a significant drug-drug interaction where the plasma concentrations of both drugs are increased. This bidirectional interaction raises safety concerns, including potential cyclosporine toxicity and an increased risk of ezetimibe-related adverse effects. Close monitoring and possible dose adjustments are required.

Question 4

A patient with severe hypercholesterolemia is found to have a rare homozygous loss-of-function mutation in the NPC1L1 gene. Which lipid-lowering agent would be expected to have virtually no efficacy in this patient?

  1. Alirocumab
  2. Atorvastatin
  3. Ezetimibe (correct answer)
  4. Fenofibrate
Explanation: Ezetimibe exerts its effect by specifically inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein, which is responsible for intestinal cholesterol absorption. If the patient has a loss-of-function mutation in the gene encoding this protein, the drug's target is non-functional or absent, rendering ezetimibe ineffective. The other agents work through different mechanisms (PCSK9 inhibition, HMG-CoA reductase inhibition, PPAR-alpha activation) that are independent of NPC1L1.

Question 5

A 58-year-old male with familial hypercholesterolemia is started on evolocumab. This therapy results in a significant reduction in his plasma LDL-C levels. The primary molecular mechanism responsible for this effect involves a drug-induced alteration in which cellular process?

  1. Increased transcription of the LDLR gene.
  2. Inhibition of cholesterol transport at the enterocyte brush border.
  3. Decreased lysosomal degradation of the LDL receptor. (correct answer)
  4. Direct allosteric activation of the LDL receptor's binding domain.
Explanation: Evolocumab is a monoclonal antibody that binds to PCSK9. PCSK9 normally targets the LDL receptor (LDLR) for lysosomal degradation after it has been internalized. By inhibiting PCSK9, evolocumab prevents LDLR degradation, increasing the number of receptors that are recycled back to the hepatocyte surface to clear more LDL-C from the plasma.

Question 6

A genetic analysis reveals a patient has a gain-of-function mutation in the PCSK9 gene, leading to increased activity of the PCSK9 protein. Compared to an individual with a normal PCSK9 gene, this patient is expected to exhibit which of the following phenotypes at baseline?

  1. Lower plasma LDL-C levels due to decreased LDL receptor degradation.
  2. Higher plasma LDL-C levels due to increased LDL receptor degradation. (correct answer)
  3. Higher plasma LDL-C levels due to impaired cholesterol absorption.
  4. Lower plasma LDL-C levels due to reduced hepatic cholesterol synthesis.
Explanation: PCSK9's function is to promote the degradation of LDL receptors (LDLRs). A gain-of-function mutation would lead to hyperactive PCSK9, resulting in excessive degradation of LDLRs. With fewer LDLRs on the surface of hepatocytes, the clearance of LDL-C from the plasma is reduced, leading to higher baseline plasma LDL-C levels and an increased risk of atherosclerotic cardiovascular disease.

Question 7

A patient's lipid panel shows a substantial decrease in LDL-C after starting therapy with a PCSK9 inhibitor. The mechanism of this drug class ultimately leads to an increase in which of the following rates?

  1. The rate of VLDL secretion from the liver.
  2. The rate of LDL receptor endocytosis and lysosomal fusion.
  3. The rate of hepatocyte LDL receptor recycling to the cell surface. (correct answer)
  4. The rate of cholesterol absorption in the jejunum.
Explanation: PCSK9 inhibitors work by binding to PCSK9, preventing it from targeting the LDL receptor (LDLR) for degradation. When the LDLR binds LDL and is endocytosed, it normally dissociates in the endosome and is recycled to the cell surface. PCSK9 binding prevents this recycling and shunts the receptor to the lysosome. By blocking PCSK9, the drug increases the rate at which LDLRs are successfully recycled back to the plasma membrane, thereby increasing the liver's capacity to clear LDL.

Question 8

A patient undergoes a significant small bowel resection, resulting in malabsorption. The patient also has atherosclerotic cardiovascular disease (ASCVD) and requires intensive lipid-lowering therapy in addition to a high-intensity statin. Which agent's lipid-lowering efficacy would be most significantly blunted by the patient's gastrointestinal condition?

  1. Alirocumab
  2. Evolocumab
  3. Rosuvastatin
  4. Ezetimibe (correct answer)
Explanation: Ezetimibe's mechanism of action is the inhibition of cholesterol absorption from the small intestine via the NPC1L1 transporter. A significant small bowel resection reduces the surface area available for cholesterol absorption, thus blunting the efficacy of a drug that targets this process. Alirocumab and evolocumab are systemically administered and act in the liver, while rosuvastatin's primary action is hepatic, making them less dependent on intestinal integrity for their primary effect.

Question 9

A patient on maximally tolerated atorvastatin has an LDL-C of 130 mg/dL. The therapeutic goal is an LDL-C < 70 mg/dL, requiring approximately a 50% further reduction. Which of the following represents the most appropriate agent to add and its corresponding mechanism?

  1. Ezetimibe, which prevents the degradation of LDL receptors on hepatocytes.
  2. Evolocumab, which inhibits cholesterol absorption via the NPC1L1 transporter.
  3. Evolocumab, which prevents the degradation of LDL receptors on hepatocytes. (correct answer)
  4. Ezetimibe, which inhibits hepatic cholesterol synthesis via HMG-CoA reductase.
Explanation: A 50% reduction in LDL-C is a substantial goal. PCSK9 inhibitors like evolocumab can provide a 50-60% reduction on top of statin therapy. Ezetimibe typically provides a more modest 15-20% reduction. The mechanism of evolocumab is to prevent PCSK9-mediated degradation of LDL receptors. The other options incorrectly match the drug to the mechanism or the required efficacy.

Question 10

A key difference between ezetimibe and alirocumab is their route of administration (oral vs. subcutaneous injection, respectively). The requirement for parenteral administration of alirocumab is due to which of its molecular properties?

  1. It requires first-pass metabolism in the liver to be converted into its active form.
  2. Its absorption is completely blocked by the NPC1L1 transporter in the intestine.
  3. It is a large protein that would be degraded by proteases in the gastrointestinal tract. (correct answer)
  4. It is a highly lipophilic molecule that is poorly soluble in the GI tract's aqueous environment.
Explanation: Alirocumab is a human monoclonal antibody, which is a large protein molecule. If administered orally, it would be denatured by stomach acid and digested by proteases in the stomach and small intestine, just like any dietary protein. Therefore, it must be administered parenterally (subcutaneously) to bypass the gastrointestinal tract and enter the systemic circulation intact.

Question 11

A patient is diagnosed with homozygous familial hypercholesterolemia (HoFH) due to receptor-negative mutations, resulting in a complete absence of functional LDL receptors. The patient is started on atorvastatin, ezetimibe, and evolocumab. Which statement best describes the expected efficacy of these agents in this patient?

  1. Evolocumab will be highly effective because it can restore function to the mutated LDL receptors.
  2. Atorvastatin and evolocumab will have severely blunted efficacy, but ezetimibe will provide a modest benefit. (correct answer)
  3. Atorvastatin and ezetimibe will work synergistically to normalize LDL-C, while evolocumab will be ineffective.
  4. All three agents will be completely ineffective as their mechanisms ultimately depend on functional LDL receptors.
Explanation: The primary mechanisms of both statins (upregulating LDLR expression) and PCSK9 inhibitors (preventing LDLR degradation) rely on the presence of functional LDL receptors to clear LDL from the blood. In a patient with no functional receptors, their efficacy is severely blunted or absent. Ezetimibe, however, works upstream by blocking cholesterol absorption from the intestine. This mechanism is independent of LDL receptor function and thus will still provide a modest LDL-lowering effect by reducing the substrate for lipoprotein production.

Question 12

Co-administration of ezetimibe with fenofibrate is generally considered acceptable, but its use with gemfibrozil is not recommended. This is because gemfibrozil, but not fenofibrate, significantly inhibits the glucuronidation of ezetimibe. This inhibition would lead to:

  1. Decreased absorption of ezetimibe from the GI tract.
  2. Accelerated renal clearance of ezetimibe, leading to loss of efficacy.
  3. Increased plasma levels of ezetimibe and its active metabolite. (correct answer)
  4. A synergistic reduction in triglycerides through a pharmacodynamic interaction.
Explanation: Ezetimibe is metabolized primarily via glucuronidation to its active form, ezetimibe-glucuronide. Gemfibrozil inhibits this metabolic pathway, leading to a significant increase in the plasma concentrations of total ezetimibe. This elevates the risk of adverse effects, such as cholelithiasis, and is the reason the combination is generally avoided. Fenofibrate does not have this same inhibitory effect.

Question 13

A patient with severe hypercholesterolemia is found to have a rare homozygous loss-of-function mutation in the NPC1L1 gene. Which lipid-lowering agent would be expected to have virtually no efficacy in this patient?

  1. Alirocumab
  2. Atorvastatin
  3. Ezetimibe (correct answer)
  4. Fenofibrate
Explanation: Ezetimibe exerts its effect by specifically inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein, which is responsible for intestinal cholesterol absorption. If the patient has a loss-of-function mutation in the gene encoding this protein, the drug's target is non-functional or absent, rendering ezetimibe ineffective. The other agents work through different mechanisms (PCSK9 inhibition, HMG-CoA reductase inhibition, PPAR-alpha activation) that are independent of NPC1L1.

Question 14

A genetic analysis reveals a patient has a gain-of-function mutation in the PCSK9 gene, leading to increased activity of the PCSK9 protein. Compared to an individual with a normal PCSK9 gene, this patient is expected to exhibit which of the following phenotypes at baseline?

  1. Lower plasma LDL-C levels due to decreased LDL receptor degradation.
  2. Higher plasma LDL-C levels due to increased LDL receptor degradation. (correct answer)
  3. Higher plasma LDL-C levels due to impaired cholesterol absorption.
  4. Lower plasma LDL-C levels due to reduced hepatic cholesterol synthesis.
Explanation: PCSK9's function is to promote the degradation of LDL receptors (LDLRs). A gain-of-function mutation would lead to hyperactive PCSK9, resulting in excessive degradation of LDLRs. With fewer LDLRs on the surface of hepatocytes, the clearance of LDL-C from the plasma is reduced, leading to higher baseline plasma LDL-C levels and an increased risk of atherosclerotic cardiovascular disease.

Question 15

The administration of evolocumab leads to a marked increase in the number of surface LDL receptors on hepatocytes. This enhanced clearance of plasma LDL results in an increased influx of cholesterol into the hepatocyte. This intracellular change would be expected to lead to what compensatory response via the SREBP-2 pathway?

  1. Decreased transcription of the HMG-CoA reductase gene. (correct answer)
  2. Increased transcription of the PCSK9 gene.
  3. Decreased transcription of the LDL receptor gene.
  4. Increased activity of the NPC1L1 transporter.
Explanation: High levels of intracellular cholesterol act as a negative feedback signal on the sterol regulatory element-binding protein 2 (SREBP-2) pathway. This pathway controls cholesterol homeostasis. The influx of cholesterol due to evolocumab will suppress SREBP-2, leading to decreased transcription of its target genes, which include both HMG-CoA reductase (for synthesis) and the LDL receptor (for uptake). Of the choices, decreased transcription of HMG-CoA reductase is a key physiological response to high intracellular cholesterol.

Question 16

A patient with established ASCVD and a very high baseline Lipoprotein(a) [Lp(a)] level is on high-intensity statin therapy. Despite achieving their LDL-C goal, their physician is concerned about the residual risk from the elevated Lp(a). The addition of which agent would be expected to produce the most clinically meaningful reduction in Lp(a) levels?

  1. Ezetimibe
  2. Evolocumab (correct answer)
  3. Colesevelam
  4. Fenofibrate
Explanation: PCSK9 inhibitors, such as evolocumab and alirocumab, have been shown to significantly reduce Lp(a) levels, typically by 20-30%. While the exact mechanism is still being elucidated, it is thought to be related to increased clearance via the LDL receptor. Other agents like ezetimibe, statins, and fibrates have minimal or negligible effects on Lp(a) concentrations.

Question 17

In a normal hepatocyte, the PCSK9 protein is synthesized and secreted. It then functions in an autocrine/paracrine fashion. Which of the following describes the critical extracellular event that is directly blocked by alirocumab?

  1. The synthesis of PCSK9 within the endoplasmic reticulum.
  2. The internalization of the LDL-LDL receptor complex into a clathrin-coated pit.
  3. The binding of secreted PCSK9 to the epidermal growth factor-like repeat A (EGF-A) domain of the LDL receptor. (correct answer)
  4. The sorting of the LDL receptor to the lysosome for degradation within the late endosome.
Explanation: Alirocumab is a monoclonal antibody that circulates in the plasma. Its mechanism of action is to bind to free, extracellular PCSK9 protein. This binding physically prevents the PCSK9 protein from interacting with its target, the EGF-A domain of the LDL receptor, on the surface of hepatocytes. The other options describe intracellular events that are either upstream or downstream of this critical drug-target interaction.

Question 18

A heart transplant recipient stabilized on a cyclosporine-based immunosuppressive regimen requires lipid-lowering therapy with ezetimibe. What is the most significant pharmacokinetic interaction of concern when these two drugs are co-administered?

  1. A significant decrease in cyclosporine levels, risking transplant rejection.
  2. A significant decrease in ezetimibe efficacy due to induced metabolism.
  3. Increased risk of myopathy independent of any change in drug concentrations.
  4. Bidirectional increase in plasma concentrations of both cyclosporine and ezetimibe. (correct answer)
Explanation: Co-administration of cyclosporine and ezetimibe results in a significant drug-drug interaction where the plasma concentrations of both drugs are increased. This bidirectional interaction raises safety concerns, including potential cyclosporine toxicity and an increased risk of ezetimibe-related adverse effects. Close monitoring and possible dose adjustments are required.

Question 19

A patient's lipid panel shows a substantial decrease in LDL-C after starting therapy with a PCSK9 inhibitor. The mechanism of this drug class ultimately leads to an increase in which of the following rates?

  1. The rate of VLDL secretion from the liver.
  2. The rate of LDL receptor endocytosis and lysosomal fusion.
  3. The rate of hepatocyte LDL receptor recycling to the cell surface. (correct answer)
  4. The rate of cholesterol absorption in the jejunum.
Explanation: PCSK9 inhibitors work by binding to PCSK9, preventing it from targeting the LDL receptor (LDLR) for degradation. When the LDLR binds LDL and is endocytosed, it normally dissociates in the endosome and is recycled to the cell surface. PCSK9 binding prevents this recycling and shunts the receptor to the lysosome. By blocking PCSK9, the drug increases the rate at which LDLRs are successfully recycled back to the plasma membrane, thereby increasing the liver's capacity to clear LDL.

Question 20

A patient is diagnosed with homozygous familial hypercholesterolemia (HoFH) due to receptor-negative mutations, resulting in a complete absence of functional LDL receptors. The patient is started on atorvastatin, ezetimibe, and evolocumab. Which statement best describes the expected efficacy of these agents in this patient?

  1. Evolocumab will be highly effective because it can restore function to the mutated LDL receptors.
  2. Atorvastatin and evolocumab will have severely blunted efficacy, but ezetimibe will provide a modest benefit. (correct answer)
  3. Atorvastatin and ezetimibe will work synergistically to normalize LDL-C, while evolocumab will be ineffective.
  4. All three agents will be completely ineffective as their mechanisms ultimately depend on functional LDL receptors.
Explanation: The primary mechanisms of both statins (upregulating LDLR expression) and PCSK9 inhibitors (preventing LDLR degradation) rely on the presence of functional LDL receptors to clear LDL from the blood. In a patient with no functional receptors, their efficacy is severely blunted or absent. Ezetimibe, however, works upstream by blocking cholesterol absorption from the intestine. This mechanism is independent of LDL receptor function and thus will still provide a modest LDL-lowering effect by reducing the substrate for lipoprotein production.